ClinicalTrials.gg
Active, not recruitingNCT06524414Updated Nov 6, 2026

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

A Phase 2 interventional study of PG4 and 20-valent pneumococcal conjugate vaccine (20vPnC) in Pneumococcal Disease, sponsored by Pfizer. Active, not recruiting at 67 sites in 2 countries. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Pfizer · Phase 2, Interventional, and Prevention

Updated Nov 6, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
605
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.

Enrollment
28th of 57
605 · median 570
Started
2024
with 2 others
Phase 2
7 of 75
none open now
Registered
66th of 75
by date

Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 28th largest by enrollment of the 57 interventional ones that give a count, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 66th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 42 Days to 98 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Pneumococcal Infections by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine.

To ensure that the new vaccine (PG4) stays stable, it is placed in a liquid mixture of sterile water and other substances (a solution). This study will also test if there is a difference in the safety and immune effects of the new pneumococcal vaccine when it is one type of solution compared to when it is in a different type of solution.

The immune response is how the body's cells; tissues and organs work together to protect the body from infection. Blood samples will be used to measure the amount of antibodies produced after the vaccination. Antibodies are proteins that protect you when an unwanted germ enters the body. This will help understand how well the new pneumococcal vaccine works. This vaccine can possibly provide protection against pneumococcal disease. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae.

This study is seeking participants who are:

  • male or female infants who are 2 months of age,
  • infants born at 36 weeks (about 8 and a half months) of pregnancy or later; and,
  • said to be healthy by the study doctor

There are four groups in this study. All participants will be assigned to one of the four groups. All study vaccines will be given as a single shot into the left thigh muscle. Participants in the three groups will have 3 blood samples collected during the 1 and a half years they are in the study.

The first 400 participants who enter the study will be assigned to either Group 1 or Group 2. Half the participants in Group 1 and half the participants in Group 2 will receive 4 doses at 2, 4, 6, and 12 to 15 months of age of PG4 mixed in the first solution. The other half of the participants in Groups 1 and 2 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age. The main difference between Groups 1 and 2 is that participants in Group 2 will have the first blood sample collected at an earlier time than those in Group 1.

Once 400 participants have been assigned to Groups 1 and 2 then 100 new participants will be assigned to Group 3. Half the participants in Group 3 will receive PG4 in the second solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Groups 3 will receive 4 doses of 20vPnC (Prevnar 20®) at 2, 4, 6, and 12 to 15 months of age.

Once the 100 participants have been assigned to Group 3 then 100 new participants will be assigned to Group 4. Half the participants in Group 4 will receive PG4 in the first solution at 2, 4, 6, and 12 to 15 months of age. The other half of the participants in Group 4 will receive 4 doses of a licensed pneumococcal comparator vaccine at 2, 4, 6, and 12 to 15 months of age.

Participants will take part in this study for about 16 to 19 months (about 1 and a half years). During this time, participants will have 6 study clinic visits and 1 to 2 phone calls. At these study clinic visits, parent(s) or legal guardian(s) will be asked if the participant experienced any side effects. A side effect is an unintentional or unexpected reaction to a vaccine.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female infants born at >36 weeks of gestation and 2 months of age at the time of consent.
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis).
  • Major known congenital malformation or serious chronic disorder.
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
605 participants (actual)

Study arms

  • Experimental
    Group 1 PG4

    Multivalent Pneumococcal Vaccine

    Biological: PG4

  • Active comparator
    Group 1 20-valent pneumococcal conjugate vaccine (20vPnC)

    20-valent pneumococcal conjugate vaccine (20vPnC)

    Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

  • Experimental
    Group 2 PG4

    Multivalent Pneumococcal Vaccine

    Biological: PG4

  • Active comparator
    Group 2 20-valent pneumococcal conjugate vaccine (20vPnC)

    20-valent pneumococcal conjugate vaccine (20vPnC)

    Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

  • Experimental
    Group 3 PG4

    Multivalent Pneumococcal Vaccine

    Biological: PG4

  • Active comparator
    Group 3 20-valent pneumococcal conjugate vaccine (20vPnC)

    20-valent pneumococcal conjugate vaccine (20vPnC)

    Biological: 20-valent pneumococcal conjugate vaccine (20vPnC)

  • Experimental
    Group 4 PG4

    Multivalent Pneumococcal Vaccine

    Biological: PG4

  • Active comparator
    Group 4 15-valent pneumococcal conjugate vaccine (PCV15)

    15-valent pneumococcal conjugate vaccine (PCV15)

    Biological: 15-valent pneumococcal conjugate vaccine (PCV15)

Interventions

  • BiologicalPG4

    Multivalent pneumococcal conjugate vaccine

  • 20-valent pneumococcal conjugate vaccine

    Also known as: Prevnar 20

  • Biological15-valent pneumococcal conjugate vaccine (PCV15)

    15-valent pneumococcal conjugate vaccine

    Also known as: PCV15

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting local reactions within 7 days after each dose

    Prompted local reactions after each dose

    Time frame: Day 7

  2. Percentage of participants reporting systemic events within 7 days after each dose

    Prompted systemic reactions after each dose

    Time frame: Day 7

  3. Percentage of participants reporting adverse events (AEs)

    AEs occurring from Dose 1 to 1 month after Dose 2

    Time frame: Dose 1 to 1 month after Dose 3

  4. Percentage of participants reporting AEs

    AEs occurring from Dose 4 to 1 month after Dose 4

    Time frame: Dose 4 to 1 month after Dose 4

  5. Percentage of participants reporting serious adverse events (SAEs)

    SAEs occurring from Dose 1 to 6 months after Dose 4

    Time frame: Dose 1 to 6 months after Dose 4

Secondary outcomes

  1. Pneumococcal immunoglobulin G (IgG) geometric mean concentrations (GMCs)

    Pneumococcal IgG GMCs 1 month after Dose 4

    Time frame: 1 month after Dose 4

07

Study locations

67 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2027, 31 months after the start.

Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 31 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion May 2027 → Mar 2027 and completion May 2027 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2024
First posted
Jul 29, 2024
StartActual
Jul 25, 2024
Primary completionEst.
Mar 4, 2027was May 2027
CompletionEst.
Mar 4, 2027was May 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 6 sites removed
Show 5 added (4 Puerto Rico, 1 United States)
  • Javara Inc. · Dallas, United States
  • Clinical Research Puerto Rico · Guayama, Puerto Rico
  • Ponce Medical School Foundation Inc. · Ponce, Puerto Rico
  • University of Puerto Rico - Medical Sciences Campus · San Juan, Puerto Rico
  • The Hispanic Alliance for Clinical and Translational Research · San Juan, Puerto Rico
Show 6 removed
  • Javara Inc a Delaware corporation · Winston-Salem, United States
  • Javara - Privia Medical Group North Texas - Dallas · Dallas, United States
  • Clinical Research Puerto Rico · Guayama, Puerto Rico
  • Ponce Medical School Foundation Inc. · Ponce, Puerto Rico
  • University of Puerto Rico - Medical Sciences Campus · San Juan, Puerto Rico
  • The Hispanic Alliance for Clinical and Translational Research · San Juan, Puerto Rico
across 2 updates, Oct 19, 2026 – Nov 6, 2026
Primary completion
May 1, 2027→Mar 4, 2027
Nov 6, 2026
Study completion
May 1, 2027→Mar 4, 2027
Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    4 sites added, 4 sites removed
    Show 4 added (4 Puerto Rico)
    • Clinical Research Puerto Rico · Guayama, Puerto Rico
    • Ponce Medical School Foundation Inc. · Ponce, Puerto Rico
    • University of Puerto Rico - Medical Sciences Campus · San Juan, Puerto Rico
    • The Hispanic Alliance for Clinical and Translational Research · San Juan, Puerto Rico
    Show 4 removed
    • Clinical Research Puerto Rico · Guayama, Puerto Rico
    • Ponce Medical School Foundation Inc. · Ponce, Puerto Rico
    • University of Puerto Rico - Medical Sciences Campus · San Juan, Puerto Rico
    • The Hispanic Alliance for Clinical and Translational Research · San Juan, Puerto Rico
    Primary completion May 1, 2027→Mar 4, 2027
    Study completion May 1, 2027→Mar 4, 2027
    + 3 other changes: identifiers, verification date and description
  2. Oct 19, 2026
    1 site added, 2 sites removed
    Show site
    • Javara Inc. · Dallas, United States
    Show 2 removed
    • Javara Inc a Delaware corporation · Winston-Salem, United States
    • Javara - Privia Medical Group North Texas - Dallas · Dallas, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06524414
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 29, 2024
Start date
Jul 25, 2024
Primary completion
Mar 4, 2027 (estimated)
Completion
Mar 4, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion